| Christopher M Herndon, MD | |
|
2635 W Elk Ave, Duncan, OK 73533-1572 | |
| (580) 252-6080 | |
| (580) 470-2966 |
| Full Name | Christopher M Herndon |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 48 Years |
| Location | 2635 W Elk Ave, Duncan, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578563672 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 11717 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Health Watch Health Care Of Duncan, Llc | Duncan, OK | Home health agency |
| Genesis Healthcare,llc | Durant, OK | Home health agency |
| Duncan Regional Hospital Homecare | Duncan, OK | Home health agency |
| Duncan Regional Hospital, Inc | Duncan, OK | Hospital |
| Jefferson County Hospital | Waurika, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duncan Regional Hospital, Inc. | 5193613057 | 31 |
News Archive
An article published today in the New England Journal of Medicine updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans.
The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.
Bankers Healthcare Group, one of the nation's leaders in financing for healthcare professionals, is pleased to announce that they have been recognized once again on the 2010 Inc. 500/5000 list as one of America's fastest-growing organizations. BHG has earned the 1839th list position among 5000 selected companies.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.
› Verified 4 days ago
| Entity Name | Solutions Practice Management |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104009299 PECOS PAC ID: 5698840775 Enrollment ID: O20081015000361 |
News Archive
An article published today in the New England Journal of Medicine updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans.
The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.
Bankers Healthcare Group, one of the nation's leaders in financing for healthcare professionals, is pleased to announce that they have been recognized once again on the 2010 Inc. 500/5000 list as one of America's fastest-growing organizations. BHG has earned the 1839th list position among 5000 selected companies.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.
› Verified 4 days ago
| Entity Name | Duncan Regional Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699318147 PECOS PAC ID: 5193613057 Enrollment ID: O20200930003440 |
News Archive
An article published today in the New England Journal of Medicine updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans.
The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.
Bankers Healthcare Group, one of the nation's leaders in financing for healthcare professionals, is pleased to announce that they have been recognized once again on the 2010 Inc. 500/5000 list as one of America's fastest-growing organizations. BHG has earned the 1839th list position among 5000 selected companies.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher M Herndon, MD 2515 W Elk Ave, Duncan, OK 73533-1571 Ph: (580) 252-6080 | Christopher M Herndon, MD 2635 W Elk Ave, Duncan, OK 73533-1572 Ph: (580) 252-6080 |
News Archive
An article published today in the New England Journal of Medicine updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans.
The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.
Bankers Healthcare Group, one of the nation's leaders in financing for healthcare professionals, is pleased to announce that they have been recognized once again on the 2010 Inc. 500/5000 list as one of America's fastest-growing organizations. BHG has earned the 1839th list position among 5000 selected companies.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.
› Verified 4 days ago
Dan F Criswell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2601 W Elk Ave, Duncan, OK 73533 Phone: 580-251-6644 Fax: 580-251-6645 | |
Krystal Marie Vonfeldt, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2120 W Elk Ave, Duncan, OK 73533 Phone: 580-251-6822 | |
William T Stewart, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 Fax: 580-252-8336 | |
Francis James Mcgouran Iii, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1334 N Harville Rd, Duncan, OK 73533 Phone: 580-255-8564 Fax: 580-255-8640 | |
Demetra G Cox, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 Fax: 580-252-8336 | |
Preston A Waters, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 | |
Dr. Mark Rosekelly, D.O Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4086 Country Club Rd Ste 2, Duncan, OK 73533 Phone: 580-952-9221 |